AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
LOQTORZI revenue grew 36% YoY to $13.6M in Q2 2026, but continuing operations posted net loss of $33.3M as R&D and SG&A expenses remained elevated.
Biggest Revenue Drivers
LOQTORZI$13.6M+37% YoY
Volume growth of LOQTORZI drove the increase.
Biggest Revenue Drivers
Total revenue: $14.3M+39% YoY
LOQTORZI$13.6M+37% YoY
Volume growth of LOQTORZI drove the increase.
Largest Expense Items
Research and development$21.4M-18% YoY
Lower internal costs including $2.3M decrease in employee-related costs; reduced manufacturing-related development activities and headcount.
Selling, general and administrative$21.0M-20% YoY
Lower average headcount and reduced operating costs following 2025 exit from biosimilar business; employee costs decreased $2.3M and professional fees decreased $2.3M.
Cost of goods sold$4.2M+25% YoY
Primarily due to volume growth of LOQTORZI; gross margin 70%.
Interest expense$2.3M+2% YoY
Interest on 2029 Term Loan and LOQTORZI portion of Revenue Purchase and Sale Agreement.
Watch Items from the Filing
Three customers (McKesson, Cencora, Cardinal) represent 42%, 40%, and 16% of gross product revenue, respectively. Loss of any major distributor could materially harm revenue.
Company had $105.3M in cash and marketable securities as of June 30, 2026 versus $172.1M at year-end 2025. Cash burn rate suggests limited runway without additional financing or meaningful LOQTORZI sales growth.
No Earnout Payments ($37.5M each) received from UDENYCA sale; revenues did not meet $300M or $350M thresholds as of June 30, 2026. Total upfront consideration remains $483.4M.
Company completed 32.9M share public offering in Q1 2026 at $1.75/share, netting $53.6M; stock price significantly below offering price indicates dilution risk and market skepticism.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
O'Donnell-Tormey JillReporting ownerGrant or award · Jun 5, 2026
Ryan Michael LeeReporting ownerGrant or award · Jun 5, 2026
Newcomer Lee NisleyReporting ownerGrant or award · Jun 5, 2026
Karachun Rita AReporting ownerGrant or award · Jun 5, 2026
Satvat Ali J.Reporting ownerGrant or award · Jun 5, 2026
Lanfear Dennis MPresident & CEODisposition to issuer · May 29, 2026
McMichael Bryan JChief Financial OfficerDisposition to issuer · May 29, 2026
Congress trading in CHRS
1 transaction in CHRS reported by 1 member of Congress under the STOCK Act, most recent trade Jan 23, 2023. Reported transactions, not recommendations.
About Coherus Oncology, Inc. (CHRS): stock profile, AI score and financials
Coherus Oncology, Inc. (CHRS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CHRS at 4.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,920 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.9) and free cash flow (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Coherus Oncology, Inc. reports quarterly revenue of $14.3M, net income of $-20.6M. Top institutional holders of CHRS by reported 13-F value include Timothy G. Youngquist 2020 Irrevocable, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CHRS trades on the Nasdaq exchange and files with the SEC under CIK 1512762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coherus Oncology, Inc. directly from SEC EDGAR.